Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Capital Expenditures (2017 - 2023)

Tenax Therapeutics' Capital Expenditures history spans 8 years, with the latest figure at $1.0 for Q4 2017.

  • On a quarterly basis, Capital Expenditures changed N/A to $1.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $4537.0, a 57.32% increase, with the full-year FY2022 number at $2323.0, down 55.77% from a year prior.
  • Capital Expenditures hit $1.0 in Q4 2017 for Tenax Therapeutics, down from $1264.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TENX hit a ceiling of $16688.0 in Q3 2015 and a floor of $1.0 in Q4 2017.
  • Historically, Capital Expenditures has averaged $6120.1 across 5 years, with a median of $2884.0 in 2016.
  • Biggest five-year swings in Capital Expenditures: tumbled 63.91% in 2013 and later surged 343.02% in 2014.
  • Tracing TENX's Capital Expenditures over 5 years: stood at $2267.0 in 2013, then surged by 332.47% to $9804.0 in 2014, then surged by 70.22% to $16688.0 in 2015, then tumbled by 82.72% to $2884.0 in 2016, then crashed by 99.97% to $1.0 in 2017.
  • Business Quant data shows Capital Expenditures for TENX at $1.0 in Q4 2017, $1264.0 in Q3 2017, and $3272.0 in Q1 2017.